PRESENTATION: Rosuvastatin 10 mg & Fenofibrate 160 mg tablets. 

DRUG CLASS: Antilipemic Agent, HMG-CoA Reductase Inhibitor 

MECHANISM OF ACTION: 

Rosuvastatin is an Inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis (reduces the production of mevalonic acid from HMG-CoA); this then results in a compensatory increase in the expression of LDL receptors on hepatocyte membranes 

and a stimulation of LDL catabolism.In addition to the ability of HMG-CoA reductase inhibitors to decrease levels of high-sensitivity C-reactive protein (hsCRP), they also possess pleiotropic properties including improved endothelial function,reduced inflammation at the site of the coronary plaque, inhibition of platelet aggregation, and anticoagulant effects. 

Fenofibrate: Fenofibric acid, an agonist for the nuclear transcription factor peroxisome proliferator-activated receptor-alpha (PPAR-alpha), downregulates apoprotein C-III (an inhibitor of lipoprotein lipase) and upregulates the synthesis of apolipoprotein A-I, fatty acid transport protein, and lipoprotein lipase resulting in an increase in VLDL catabolism, fatty acid oxidation, and elimination of triglyceride-rich particles; as a result of a decrease in VLDL levels, total plasma triglycerides are reduced by 30% to 60%; modest increase in HDL occurs in some hypertriglyceridemic patients. 

INDICATIONS : Hyperlipidemia and Mixed Dyslipidemia, Hypertriglyceridemia, Primary 

Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), Homozygous, Familial Hypercholesterolemia 

Slowing of the progression of atherosclerosis, Primary Prevention of Cardiovascular Disease. 

DOSAGE: As Directed by the Physician